Prochaines mises à jour
pour 2026-2027
Quick Take Vol. 93
Substitution des antipsychotiques en pratique clinique
Guide du brexpiprazole : pharmacologie, indications, posologie et effets indésirables
Prise en charge du TDAH complexe – Interview
Quick Take Vol. 94
Pharmacothérapie du trouble lié à l'usage du cannabis
Guide de l'aripiprazole : pharmacologie, indications, posologie et effets indésirables
Quick Take Vol. 95
Citalopram et escitalopram : résumé des principales différences et similitudes (mise à jour 2026)
L'algorithme de psychopharmacologie pour la dépression psychotique
Guide du lithium : pharmacologie, indications, posologie et effets indésirables
Quick Take Vol. 96
Psychopharmacologie chez les adultes présentant une déficience intellectuelle : quand prescrire, quand arrêter
Interactions médicamenteuses en psychopharmacologie
Guide de l'atomoxétine : pharmacologie, indications, posologie et effets indésirables
Quick Take Vol. 97
Guide pratique sur la fluvoxamine : pharmacologie, indications, posologie et effets indésirables (mise à jour 2027)
Pharmacothérapie des troubles liés à l'usage de substances pendant la grossesse
Guide du méthylphénidate : pharmacologie, indications, posologie et effets indésirables
Psychopharmacologie de la prise de poids et de l'obésité
Quick Take Vol. 98
Trop de doses, trop de médicaments : plafonds posologiques et polymédication en psychiatrie
Guide des amphétamines : pharmacologie, indications, recommandations posologiques et effets indésirables
Guide sur la venlafaxine : pharmacologie, indications, posologie et effets indésirables (mise à jour 2027)
Psychopharmacologie de l'autisme
Quick Take Vol. 99
Médicaments du TDAH : un guide complet des formulations
Le trouble bipolaire durant la période périnatale
Quick Take Vol. 100
Quick Take Vol. 101
Guide de la desvenlafaxine : pharmacologie, indications, posologie et effets indésirables (mise à jour de 2027)
Quick Take Vol. 102
Quick Take Vol. 103
Guide de la duloxétine : pharmacologie, indications, posologie et effets indésirables (Mise à jour de 2027)
Quick Take Vol. 104
CME Information
Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour.
All of our content is psychopharmacology, so the pharmacology hours shown on your certificate match the credits awarded for that activity. Your certificate states them on their own line, separately from the credit designation statement.
This applies to APRN pharmacology renewal as well. Boards of nursing define pharmacology CE in their own way, so please confirm with your board that this is the documentation they expect.
Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The NCCPA accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME toward PA certification maintenance. Requirements are set by the NCCPA, so please confirm with them what your current cycle requires.
Physicians outside the United States – CME Accreditation Statement

AMA PRA Category 1 Credit™ may be awarded to any physician, whether or not they are licensed in the United States. The requirements are the same.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.
Whether these credits count toward your own national continuing education requirement is decided by your national medical chamber or society, and the rules differ from country to country. We recommend confirming with them before relying on the credits for a licensing or recertification requirement.
Self Assessment for MOC – Accreditation Statement
- Psychopharmacology Institute Self-Assessment Program 2026
Dates: April 1, 2026 – April 1, 2029
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2026 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment Program 2025
Dates: April 1, 2025 – April 1, 2028
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
- Psychopharmacology Institute Self-Assessment Program 2024
Dates: April 1, 2024 – April 1, 2027
The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.
